Sugi Predict

Sugi Predict / Compounds / SCHEMBL7941258

SCHEMBL7941258

SCHEMBL7941258

CCCCC(C)(C)C(=O)OCC

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 3/20 0.69
▸ CYP4A11 Q02928 3/20 0.69
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ MAPT P10636 1/20 0.47
▸ ATM Q13315 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ PKM P14618 3/20 0.44
▸ THRB P10828 1/20 0.44
▸ HTT P42858 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.39
▸ ELANE P08246 2/20 0.38
▸ MMP8 P22894 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ PPARA Q07869 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ PPARG P37231 1/20 0.37
▸ ABCB11 O95342 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2737131 0.94 CYP4F2 (0.72) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL29073392 0.92 CYP4F2 (0.76) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL2720899 0.92 CYP4F2 (0.76) CYP4F2CYP4A11MEN1KMT2AMAPT
Bromide SCHEMBL29061762 0.92 CYP4F2 (0.70) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL26632616 0.92 CYP4F2 (0.76) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL8249184 0.92 CYP4F2 (0.76) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL22748706 0.92 CYP4F2 (0.76) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL21060863 0.92 CYP4F2 (0.76) CYP4F2CYP4A11MEN1KMT2AMAPT
SCHEMBL28461478 0.91 CYP4F2 (0.64) CYP4F2CYP4A11MEN1KMT2AMAPT
Bromide SCHEMBL28843573 0.90 CYP4F2 (0.68) CYP4F2CYP4A11MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1893910-A Cyclic siloxane compositions for active ingredient release GEN ELECTRIC (US) 2007-01-10 — — CN claimed
US-20240423937-A1 METHODS OF TREATING PAIN AND USES THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2024-12-26 — — US disclosed
US-20240156765-A1 METHODS OF NEUROPROTECTION AND USES THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2024-05-16 — — US disclosed
US-20240041808-A1 METHODS OF NEUROPROTECTION AND USES THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2024-02-08 — — US disclosed
EP-4199905-A1 METHODS OF NEUROPROTECTION AND USES THEREOF Oculotherapy, LLC (US) 2023-06-28 — — EP disclosed
US-20230150941-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2023-05-18 — — US disclosed
WO-2023028490-A1 METHODS OF TREATING PAIN AND USES THEREOF OCULOTHERAPY, LLC (US) 2023-03-02 — — WO disclosed
CN-109952360-B Quantum dot dispersion, self-luminous photosensitive resin composition, color filter manufactured using the same, and image display device 东友精细化工有限公司 2022-03-22 — — CN disclosed
WO-2022040622-A1 METHODS OF NEUROPROTECTION AND USES THEREOF OCULOTHERAPY, LLC (US) 2022-02-24 — — WO disclosed
CN-110475827-B Radiation curable ink compositions, printed articles, and methods of using the same 花王株式会社 2022-02-15 — — CN disclosed
US-4096342-A 8β,12α,15β-PGE2 compounds THE UPJOHN COMPANY (US) 1978-06-20 — — US disclosed
US-4095036-A 8β,12α,15β-PGF2 β Compounds THE UPJOHN COMPANY (US) 1978-06-13 — — US disclosed
US-4084063-A PROSTAGLANDINS; ANTIULCER AGENTS, ANTICOAGULANTS, OXYTOCICS, DECONGESTANTS THE UPJOHN COMPANY (US) 1978-04-11 — — US disclosed
US-4067891-A 2A,2B-Dihomo-16,16-dimethyl-PGF2 analogs THE UPJOHN COMPANY (US) 1978-01-10 — — US disclosed
US-4001300-A ANTIULCER, DECONGESTANT, LABOR INDUCER, WOUND HEALER THE UPJOHN COMPANY (US) 1977-01-04 — — US disclosed
US-3987085-A PROSTAGLANDINS THE UPJOHN COMPANY (US) 1976-10-19 — — US disclosed
US-3987072-A CIS-4,5-Didehydro-15- or 16-alkylated 11-deoxy-PGE1 analogs THE UPJOHN COMPANY (US) 1976-10-19 — — US disclosed
US-3969396-A 8β, 11β, 12α-PGE2 compounds THE UPJOHN COMPANY (US) 1976-07-13 — — US disclosed
US-3954833-A PROSTAGLANDINS THE UPJOHN COMPANY (US) 1976-05-04 — — US disclosed
US-3933889-A 4,5-Cis-didehydro-PGF1.sub.α analogs THE UPJOHN COMPANY (US) 1976-01-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240041808-A1 METHODS OF NEUROPROTECTION AND USES THEREOF NLN, BDNF, GAP43 CYP4F2 4384/4885CYP4A11 4160/4885MEN1 3785/4885
US-20240423937-A1 METHODS OF TREATING PAIN AND USES THEREOF ACHE, PDE6G, PTGES3 CYP4F2 2427/4885CYP4A11 1307/4885MEN1 4022/4885
US-20240156765-A1 METHODS OF NEUROPROTECTION AND USES THEREOF NLN, BDNF, GAP43 CYP4F2 4384/4885CYP4A11 4160/4885MEN1 3785/4885
US-20230150941-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS GABBR1, GABBR2, GABRE CYP4F2 503/4885CYP4A11 404/4885MEN1 1443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.